Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Lingjuan Zeng is a leading surgical oncologist specializing in minimally invasive thyroid cancer treatment, with a particular focus on robotic-assisted techniques. Her research centers on comparing the safety, efficacy, and quality-of-life outcomes of robotic thyroidectomy (RT) versus traditional open surgery (OT). In her landmark 2023 prospective cohort study (19 citations), Dr. Zeng demonstrated that RT significantly reduces the rate of postoperative hypoparathyroidism—a debilitating complication—while maintaining comparable oncologic efficacy and improving patient quality of life. Her 2024 observational cohort study (5 citations) further advanced the field by introducing a dynamic risk assessment system incorporating radioactive iodine (RAI) therapy evaluation, showing that super-meticulous capsular dissection during RT enhances both safety and treatment precision. These contributions have established Dr. Zeng as a pioneer in robotic endocrine surgery, providing robust evidence that minimally invasive approaches can achieve superior functional outcomes without compromising cancer control. Her work is widely cited by surgeons and endocrinologists seeking to optimize thyroid cancer management, and she continues to shape clinical guidelines through rigorous prospective and observational data.